Tweet Send to a Friend Get Alerts PFE Hot Sheet Price: $28.77 -0.83% Overall Analyst Rating: BUY (= Flat) Dividend Yield: 3.3% Revenue Growth %: -9.4% Trade PFE Now! Join SI Premium – FREE Pfizer, Inc. (NYSE: PFE) is pleased to announce that the United States Food and Drug Administration (FDA) has approved DUAVEE (conjugated estrogens/bazedoxifene) 0.45mg / 20mg tablets, a novel therapy for women with a uterus, for the treatment of moderate-to-severe vasomotor symptoms associated with menopause and the prevention of postmenopausal osteoporosis [1]. When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at...
↧